布地格福吸入剂治疗慢阻肺的疗效及对CRP、SaO_(2)的影响  

Efficacy of Budesonide,Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on CRP,SaO_(2)Levels

作　　者：姚晴 YAO Qing(Department of Respiratory and Critical Care Medicine,Yiyang County People's Hospital,Yiyang 334400,Jiangxi,China)

机构地区：[1]弋阳县人民医院呼吸与危重症医学科,江西弋阳334400

出　　处：《医学信息》2024年第20期80-83,共4页Journal of Medical Information

摘　　要：目的研究布地格福吸入剂治疗慢阻肺的疗效及对CRP、SaO_(2)水平影响。方法选取2019年4月-2023年5月我院诊治的98例慢阻肺患者为研究对象,采用随机数字表法分为对照组(n=49)和观察组(n=49)。对照组采用布地奈德福莫特罗粉吸入剂治疗,观察组采用布地格福吸入剂治疗,比较两组临床疗效、慢阻肺症状评分(CAT)、血清C反应蛋白(CRP)、动脉血氧饱和度(SaO_(2))、呼吸困难症状评分(SGRQ)、不良反应发生率。结果观察组治疗总有效率为95.92%,高于对照组的81.63%(P<0.05);两组治疗后CAT评分、SGRQ评分、CRP低于治疗前,SaO_(2)大于治疗前,且观察组CAT评分、SGRQ评分、CRP低于对照组,SaO_(2)大于对照组(P<0.05);观察组不良反应发生率为6.12%,低于对照组的14.29%(P<0.05)。结论布地格福吸入剂治疗慢阻肺的临床疗效确切,可抑制炎症反应,改善血气指标,降低不良反应发生几率。Objective To study the efficacy of budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol in the treatment of chronic obstructive pulmonary disease and its effect on CRP and SaO_(2)levels.Methods A total of 98 patients with chronic obstructive pulmonary disease diagnosed and treated in our hospital from April 2019 to May 2023 were selected as the research objects.They were divided into control group(n=49)and observation group(n=49)by random number table method.The control group was treated with budesonide formoterol powder inhalation,and the observation group was treated with budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol.The clinical efficacy,chronic obstructive pulmonary symptom score(CAT),serum C-reactive protein(CRP),arterial oxygen saturation(SaO_(2)),dyspnea symptom score(SGRQ)and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 95.92%,which was higher than 81.63%in the control group(P<0.05).After treatment,the CAT score,SGRQ score and CRP in the two groups were lower than those before treatment,SaO_(2)was higher than that before treatment,and the CAT score,SGRQ score and CRP in the observation group were lower than those in the control group,SaO_(2)was higher than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was 6.12%,which was lower than 14.29%in the control group(P<0.05).Conclusion The clinical efficacy of budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol in the treatment of chronic obstructive pulmonary disease is definite,which can inhibit the inflammatory reaction,improve the blood gas index and reduce the incidence of adverse reactions.

关 键 词：布地格福吸入剂 慢阻肺 C反应蛋白 动脉血氧饱和度 

分 类 号：R563[医药卫生—呼吸系统]